NasdaqGS:WEN
NasdaqGS:WENHospitality

Assessing Wendy's (WEN) Valuation After The New Biggie Deals And Project Fresh Push

What Wendy's new Biggie Deals launch could mean for the stock Wendy's (WEN) has rolled out a refreshed Biggie Deals menu with $4, $6, and $8 options, tying this value push directly to its Project Fresh plan to lift guest experience and profitability. See our latest analysis for Wendy's. At a share price of $8.53, Wendy's has seen a 1-day share price return of 0.59% and a 30-day share price return of 2.16%. Its 1-year total shareholder return of 39.09% and 3-year total shareholder return of...
NYSE:MUX
NYSE:MUXMetals and Mining

McEwen (MUX) Uses Tartan Drill Success To Quietly Recast Its Long-Term Production Ambitions

McEwen Inc. recently reported final drill results for the Tartan Mine in Manitoba and secured an Environmental Impact Assessment extension for El Gallo in Mexico, clearing the way for mill construction and informing an updated Mineral Resource Estimate expected by late February 2026. These developments highlight how McEwen is working to expand its resource base and advance projects that could underpin its longer term production goals. Now we will examine how the Western Flank drill success...
NYSE:G
NYSE:GProfessional Services

How Genpact’s Agentic AI Research and Orchestration Strategy Will Impact Genpact (G) Investors

In early January 2026, Genpact released research showing how only 12% of organizations are progressing toward autonomous enterprises by embedding agentic AI into core workflows, underpinned by four enablers: process orchestration, AI fluency, data-centric architecture, and accelerated governance. The study not only positions Genpact’s agentic operations approach at the center of this shift, but also reveals sizable capability gaps, such as limited AI training and minimal agentic...
NYSE:GLW
NYSE:GLWElectronic

A Look At Corning (GLW) Valuation After Analyst Upgrades And Rising AI Data Center Expectations

Why Corning stock is back in the spotlight Corning (GLW) is drawing fresh attention after a series of analyst upgrades and upbeat media coverage tied to its role supplying optical components for AI driven data centers and next generation devices. See our latest analysis for Corning. Those upgrades and media mentions have arrived alongside strong price action, with Corning’s share price up 9.6% over the past week and a 1 year total shareholder return of 93.5%. This suggests that momentum has...
NasdaqGS:CRDO
NasdaqGS:CRDOSemiconductor

A Look At Credo Technology Group (CRDO) Valuation As AI Connectivity Demand And Analyst Praise Build

Credo Technology Group Holding (CRDO) is back in the spotlight as investor interest in AI focused semiconductors and data center infrastructure converges with fresh analyst attention and the company’s appearance at Needham’s Growth Conference. See our latest analysis for Credo Technology Group Holding. Recent trading has been choppy, with a 1 day share price return of 4.92% decline from US$149.12. This contrasts with a solid 7 day and 30 day share price return. The 1 year total shareholder...
NYSE:MS
NYSE:MSCapital Markets

Morgan Stanley (MS) Earnings Surge And Margin Strength Challenge Cautious Growth Narratives

Morgan Stanley (MS) has wrapped up FY 2025 with fourth quarter revenue of US$17.9b and basic EPS of US$2.72, capping a twelve month run that produced total revenue of US$70.3b and basic EPS of US$10.32, alongside a 26.9% rise in earnings and a net profit margin of 23.1% compared with 20.8% the year before. Over the past six quarters, the bank has seen quarterly revenue move from US$15.3b in Q3 2024 to US$17.9b in Q4 2025, while quarterly basic EPS moved from US$1.91 to US$2.72. This set up a...
NasdaqGM:AXSM
NasdaqGM:AXSMPharmaceuticals

Assessing Axsome Therapeutics (AXSM) After An 86% One-Year Share Price Surge

Wondering if Axsome Therapeutics at around US$174 a share still offers value, or if most of the opportunity has already been priced in? This article is built to help you frame that question clearly. The stock has seen a 3.9% return over the past week and 18.6% over the last 30 days, while year to date it is at a 2.5% decline and up 85.9% over the last year and 155.9% over three years, with a 129.4% return over five years. Recent coverage of Axsome has focused on its position in...
NasdaqGS:TER
NasdaqGS:TERSemiconductor

Is Teradyne (TER) Pricing In Too Much Optimism After 66% One-Year Surge

If you are wondering whether Teradyne's current share price lines up with its underlying worth, the next sections will walk through what the numbers are really saying about value. Teradyne's stock last closed at US$227.70, with returns of 5.3% over 7 days, 18.4% over 30 days, 9.7% year to date, 66.2% over 1 year, 145.7% over 3 years and 65.7% over 5 years. These figures have naturally raised questions about how much of this is already reflected in the price. Recent coverage has focused on...
NYSE:DEI
NYSE:DEIOffice REITs

Is Douglas Emmett (DEI) Now Attractive After Prolonged Share Price Weakness And Office Market Concerns

If you are wondering whether Douglas Emmett is priced attractively today, or if the share price still does not reflect its underlying real estate assets, this article explains what the current market value might be telling you. The stock recently closed at US$10.97, with returns of a 1.6% decline over 7 days, a 4.8% decline over 30 days, a 0.9% decline year to date, a 32.8% decline over 1 year and a 51.5% decline over 5 years. This performance may have changed how investors view its risk and...
NasdaqGS:ENVX
NasdaqGS:ENVXElectrical

Assessing Enovix (ENVX) Valuation After Independent Validation Of AI-1 Smartphone Battery Performance

Why the AI-1 testing update matters for Enovix (ENVX) stock Recent independent testing by Polaris Battery Labs confirmed the Enovix (ENVX) AI-1 smartphone battery reaches 935 Wh/L volumetric energy density, about 12% above a leading silicon-doped commercial smartphone battery. For you as a shareholder or potential investor, this third-party validation of the Enovix patented 100% active silicon anode architecture raises practical questions, such as how quickly this technology could see...
NYSE:BROS
NYSE:BROSHospitality

Assessing Dutch Bros (BROS) Valuation After Recent Share Price Volatility

What Dutch Bros stock’s recent performance tells you Dutch Bros (BROS) has traded softly in the short term, with a 2.2% one day move and a 3% decline over the past week, while still showing a positive return over the past 3 months. See our latest analysis for Dutch Bros. With the share price at US$61.14, Dutch Bros has seen short term share price pressure, but the 90 day share price return of 11.35% and 3 year total shareholder return of 79.82% point to longer term investors having been...
NasdaqGS:SWKS
NasdaqGS:SWKSSemiconductor

Skyworks’ New Wi-SUN, LoRaWAN and Auto RF Portfolio Might Change The Case For Investing In SWKS

At CES 2026, Skyworks Solutions introduced the SKY66424-11, an integrated Wi-SUN/LoRaWAN RF front-end module for smart home and smart city uses, alongside new automotive-grade connectivity and e-mobility solutions. This push into advanced RF front-end, automotive GNSS, V2X and Bluetooth range extension highlights Skyworks’ effort to broaden beyond smartphones into infrastructure and transport connectivity. We’ll now examine how Skyworks’ push into Wi-SUN, LoRaWAN and automotive...
NYSE:PCG
NYSE:PCGElectric Utilities

PG&E (PCG) Valuation Check After Recent Share Price Momentum And Conflicting Fair Value Signals

PG&E (PCG) has been drawing fresh attention after its recent share move, with the stock up about 3% over the past month even though its return over the past 3 months remains in negative territory. See our latest analysis for PG&E. At a share price of $15.78, PG&E’s 30 day share price return of 3.34% contrasts with its year to date share price return of a 3.01% decline and 1 year total shareholder return of a 6.15% decline, which together indicate that recent momentum has picked up relative to...
NasdaqGS:NBIX
NasdaqGS:NBIXBiotechs

A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Head To Head Clinical Data

Clinical data and why it matters for Neurocrine Biosciences (NBIX) Neurocrine Biosciences (NBIX) put fresh clinical data for INGREZZA in front of investors, showing higher VMAT2 target occupancy and greater potency versus AUSTEDO XR at therapeutic doses, based on PET imaging in a head to head study. This kind of direct comparison in a recognized scientific setting can influence how physicians think about treatment choices for tardive dyskinesia and Huntington’s disease chorea. It can also...
NasdaqGS:PYPL
NasdaqGS:PYPLDiversified Financial

Assessing PayPal Holdings (PYPL) Valuation After Recent Multi‑Timeframe Share Price Declines

PayPal Holdings (PYPL) has been under pressure recently, with the stock showing a 7% decline over the past month and a 16% decline over the past 3 months, prompting closer attention from investors. See our latest analysis for PayPal Holdings. Those short term share price declines sit against a weaker backdrop, with a year to date share price return of 2.4% and a 1 year total shareholder return of 36.04% in the red. This suggests momentum has been fading as investors reassess growth prospects...
NYSE:MTX
NYSE:MTXChemicals

Is Minerals Technologies (MTX) Pricing Look Attractive After Recent Share Price Rebound

If you are wondering whether Minerals Technologies at around US$67.64 is offering good value or not, you are asking the right question for this stock. The share price has moved by 3.8% over the last 7 days, 8.9% over the last 30 days and 10.6% year to date, while the 1 year return sits at a 9.8% decline and the 3 and 5 year returns are 6.5% and 5.6% respectively. Recent attention on Minerals Technologies has been driven by ongoing interest in materials names and how they are priced relative...
NasdaqGS:RXRX
NasdaqGS:RXRXBiotechs

Assessing Recursion Pharmaceuticals (RXRX) Valuation After JP Morgan Update And REC-4881 Clinical Milestones

Why Recursion’s conference update is back on investors’ radar Recursion Pharmaceuticals (RXRX) is back in focus after its updated investor presentation at the J.P. Morgan Healthcare Conference highlighted early REC-4881 data in familial adenomatous polyposis and a cash runway the company expects to last through 2027. See our latest analysis for Recursion Pharmaceuticals. While the updated J.P. Morgan Healthcare Conference presentation and upcoming conference appearances have put Recursion...
NYSE:VST
NYSE:VSTRenewable Energy

Is It Too Late To Consider Vistra (VST) After Its Strong Share Price Rally

Investors may be wondering if Vistra at around US$180 a share still offers value, or if most of the opportunity has already played out for new investors stepping in now. The stock has recently moved sharply, with a 19.6% return over the past 7 days, 3.9% over 30 days and a 9.0% return year to date, on top of a very large 3 year return and an 845.5% return over 5 years that may have changed how the market views its risk and reward profile. These moves sit against a backdrop of ongoing...
NYSE:NUE
NYSE:NUEMetals and Mining

Does Morgan Stanley’s Cautious Steel Outlook Reshape the Bull Case for Nucor’s (NUE) Demand Backlog?

Nucor recently invited investors to a conference call held on January 27, 2026, where Chair, President and CEO Leon Topalian reviewed the company’s fourth quarter 2025 results and took questions on business conditions. Ahead of that call, Morgan Stanley shifted to a more cautious stance on Nucor, citing balanced risk-reward as softer steel demand could pressure pricing even as management pointed to stronger order backlogs in energy, infrastructure, data centers and manufacturing. Next, we’ll...
NasdaqGS:INTC
NasdaqGS:INTCSemiconductor

Is It Too Late To Consider Intel (INTC) After Its Recent Share Price Surge?

To understand whether Intel stock still offers value at today’s price, you need more than just a headline view. You need to see how its current market price lines up against different ways of estimating what the business might be worth. Intel’s share price recently closed at US$48.31, with returns of 17.5% over the last 7 days, 29.5% over the last 30 days, 22.7% year to date, 145.6% over 1 year, and 76.3% over 3 years, while the 5 year return sits at a 14.5% decline. This gives a mixed...
NasdaqGS:GEHC
NasdaqGS:GEHCMedical Equipment

Why GEHC’s UBS Downgrade Amid New AI Partnership Could Reframe Its Long-Term Innovation Story

NXP Semiconductors and GE HealthCare announced a collaboration to apply secure, low-latency edge AI to anesthesia delivery and neonatal monitoring, showcasing hands-free operating-room controls and on-device infant safety alerts at CES 2026. This partnership underscores GE HealthCare’s push to embed responsible, explainable AI into medical workflows, potentially reshaping how clinicians interact with equipment in critical-care settings. We’ll now examine how the UBS downgrade, set against GE...
NYSE:TPL
NYSE:TPLOil and Gas

Texas Pacific Land (TPL) Valuation Check After Data Center Deal And Planned Stock Split

Texas Pacific Land (TPL) has drawn fresh attention after agreeing with Bolt Data & Energy to build large-scale data center campuses on its West Texas acreage, along with plans for a three-for-one stock split in December 2025. See our latest analysis for Texas Pacific Land. The recent data center plan and upcoming stock split arrive during a period of strong short term momentum, with a 30 day share price return of 20.97% and a 7 day gain of 9.24%. However, the 1 year total shareholder return...
NYSE:ABT
NYSE:ABTMedical Equipment

Assessing Abbott Laboratories (ABT) Valuation After The CES 2026 Launch Of Libre Assist AI Tool

Abbott Laboratories (ABT) is back in focus after unveiling Libre Assist, an AI driven feature within its Libre app at CES 2026. The new tool is aimed at helping U.S. diabetes patients anticipate food related glucose responses. See our latest analysis for Abbott Laboratories. Despite the buzz around Libre Assist and interest in upcoming earnings and the proposed Exact Sciences deal, Abbott's recent share price has been relatively soft, with a 90 day share price return showing a 3.9% decline...
NYSE:WCC
NYSE:WCCTrade Distributors

Why WESCO International (WCC) Is Up 6.1% After Fresh Institutional Buying And Bullish Analyst Support

In recent weeks, Heartland Advisors disclosed a new position in WESCO International and highlighted the distributor’s improving growth prospects and margin potential, while several Wall Street firms reiterated positive ratings. This combination of fresh institutional interest and broadly supportive analyst commentary has sharpened investor attention on WESCO’s operational efficiency and earnings trajectory. With WESCO’s shares advancing over the past week, we’ll examine how Heartland’s...